123results about How to "No side effect" patented technology

A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient.

A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.

A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.

This invention provides compounds which are represented by a general formula [I][in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Indirect method invocation of methods that only return constant values is optimized using fetching operations and return constant tables. Such method calls can be optimized if all possible method calls via the call site instruction return a constant value and have no side effects. Each constant return value is loaded from a return constant table, and method invocation is eliminated. If all possible target methods in a program result in a constant return value and have no side effects, an associated virtual function dispatch table (vtable) may be used as the return constant table. Furthermore, control operation optimization may be applied to identify type constraints, based on one or more possible type-dependent constant return values from an indirect method invocation. An optimizer identifies and maps between a restricted set of values and an associated restricted set of types on which execution code may operate relative to a given control operation. The type constraints are used to optimize the associated execution code by filtering propagation of runtime type approximations for optimization.

Provided is a color light therapy device. The color light therapy device includes: a body that is used by being attached to a color light therapy portion of a human body by using a double-sided adhesive tape, a hydrogel pad, or an air suction plate, and includes a printed circuit board (PCB) that supplies driving power to a light source that emits color light in a given wavelength range to perform color light therapy on the human body; and a power jack that is connected to the PCB of the body through an electric wire. Since a user may use the color light therapy device by connecting the power jack to a mobile phone, a PC, a laptop, a tablet PC, a smartphone, a personal digital assistant (PDA), a vehicle, or a socket at home while carrying the color light therapy device, anyone may conveniently use the color light therapy device to perform color light therapy on the human body without exchanging or charging a battery.

The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.

The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.

The present invention provides a novel sewing-free hot melt adhesive TPU leather and a preparation method thereof. The hot melt adhesive TPU leather comprises a release paper, a hot melt adhesive film, and a TPU film. The release paper comprises a bottom paper layer, an adhesive layer, a plastic layer, a transition layer, and a release layer; a hot melt adhesive raw material comprises polyester polyol, diisocyanate, polyether polyol, and a plurality of additives; and a TPU raw material comprises polymer polyol, 1,4-cyclohexane-diisocyanate, a chain extender, and a plurality of functional additives. According to the present invention, innovations are conducted on raw material components of the release paper, the hot melt adhesive, and the TPU film, and extrusion shaping is conducted by utilizing the hot melt adhesive with strong plasticity and the TPU thin film; and the prepared sewing-free TPU leather has the technical advantages of firm adhesion, durability, environmentally-friendly materials, no invisible harm to human body, and the like.

Disclosed are uses of rare earth element selected from the group consisting of cerium (Ce), praseodymium (Pr), promethium (Pm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), scandium (Sc), yttrium (Y), lanthanum (La), neodymium (Nd), samarium (Sm), gadolinium (Gd), ruthenium (Lu) and mixtures thereof, or a salt or an oxide thereof for preventing hair loss, promoting hair regrowth and hair growth, removing and preventing dandruff, or promoting black hair formation.

This invention has published a composition of medicine and its preparation, which can treat diabetes, hyperlipemia, fatigue and hypoxia. The preparation is as following: 300-1000 part-by-weight of prepared rehmannia root, 150-600 part-by-weight of prepa red dogwood fruit, 100-450 part-by-weight of tree peony bark, 150-600 part-by-weight of chinese yam, 100-450 part-by-weight of indian bread, 100-450 part-by-weight of alisma rhizome, right amount of refined edible vegetable oil are the materials; the tree peony bark is distilled; the residue of the tree peony bark after distillation, the prepared rehmannia root, the chinese yam and the indian bread are decocted to get the mixed liquor; the paeonol mother liquor is added into the mixed liquor to get extracturm I by centrifugation and concentration; the prepared dogwood fruit and the alisma rhizome are extracted in the refluxing alcohol; the extract is concentrated to get extracturm II; the extracturm I and II are mixed and concentrated to the thick paste; the thick paste is dehydrated in the vacuum, smashed and sifting; The refined paeonol is smashed and added into the extracturm powder; the mixed powder is added with right amount of supplementary materials and milled by the colloid mill, sifting screening; the fine powder is made into soft capsule. The invented capsule has the features of bringing into play in a shorter time, better curative effect and lower dose for oral administration, easier to administrate and stable product quality.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I)(wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The present invention relates to a synergistic herbal formulation comprising an active fraction from Azadirachta indica designated as Fraction A and a fraction from Citrullus colocynthis designated as Fraction B, along with a fraction C containing an antioxidant from Cucumis sativus extract; and pharmaceutically accepted a carrier wherein the ratio of the components ranging between about 2 to 5.5% of fraction A; about 0.5 to 2.5% of fraction B; about 0.1-0.4% of extract of Cucumis sativus; and about 82-97% of carrier or additive.

The present invention provides a prophylactic / therapeutic agent for an allergic disease caused by Th2 cell-polarized activation, which comprises at least one kind selected from a branched amino acid, glycine, serine, arginine, a keto acid thereof and a salt thereof. Because the prophylactic / therapeutic agent of the present invention produces almost no side effects, it can be safely ingested routinely and can be taken for a long time. When the prophylactic / therapeutic agent of the present invention is used in combination with an anti-inflammatory drug, the dose of the anti-inflammatory drug can be reduced. Hence, the prophylactic / therapeutic agent of the present invention is useful for the prevention or treatment of an allergic disease caused by Th2 cell-polarized activation. The prophylactic / therapeutic agent of the present invention is particularly effective on bronchial asthma and pulmonary fibrosis that accompanies bronchial asthma.

Provided are a pancreas perfusion apparatus capable of administering a drug only to the pancreas and strictly suppressing a leakage of the drug outside the pancreas and a method for controlling the same. The apparatus includes: a first vein occlusion section occluding a vein through which a venous blood from the pancreas flows; a second vein occlusion section occluding a vein into which a venous blood from collateral pathways outside the pancreas flows; an artery occlusion section occluding sites where an artery that nourishes the pancreas is connected to arteries that nourish other tissues; a drug administration section recovering a liquid upstream of the first vein occlusion section and supplying the recovered liquid to the artery; a systemic circulation section recovering a liquid upstream of the second vein occlusion section and feeding the recovered liquid into a systemic circulation; and a control device controlling the systemic circulation pump.

The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.

The present invention is referred to an endoscopic implantable device for the apposition of the stomach walls for reducing the stomach internal volume, comprising a cylindrical elongated body comprising two hinged halves, each of which having a plurality of suction nozzles and a set of aligned grabbing teeth. Said suction nozzles have a fluid communication with a suction port of the endoscopic apparatus used to place said device into the patient's stomach, and the mentioned teeth of each half cooperate between each other to grab and keep the walls of the stomach together until the device is dissolved by the gastric fluids present in the stomach. The purposed invention also comprises a method for joining internal body tissue.

The invention relates to apparatus and methods for apparatus for detecting presence or monitoring profession of a disease in a biological subject, comprising a chamber in which the biological subject passes through, and at least one detection transducer in the chamber; wherein at least two types of information among the chemical composition, cellular classification, and molecular classification of the biological subject, are detected and collected for analysis as to whether the disease is likely to be present or progressing with the biological subject.

The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH2 or Coumaric acid-LG-NH2 as an active ingredient, which inhibits tyrosinase activity and melanin production, thereby showing an excellent skin whitening effect, and having no side effects to the skin by using a peptide component.

This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-α and thioredoxin significantly, and increases phospho-NFκB. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical / pharmaceutical and health food compounds for preventing or treating Hepatitis C.

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content.There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.